TrialDiabetologia2022
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
Simke W Waijer et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
29 papers cite it
this paperpooled ittrialcites it